NESS ZIONA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, today announced that it will dedicate capacity at its ...
NESS ZIONA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, ...
Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference NESS ZIONA, Israel, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 ...
Faster, Simpler, Better: Dramatically Reduce Timelines, Simplify Study Start up, and Increase Quality in Hundreds of Clinical Trials Each Year “This new collaboration with MRT will seek to solve two ...
NESS ZIONA, Israel, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Company is seeking partnerships for the most advanced long-acting depot injections in its pipeline, including Anastrozole Depot and Semaglutide Depot NESS ZIONA, Israel, June 01, 2026 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results